Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Salvage Therapy With Idarubicin in Relapsing CNS Lymphoma

This study has been terminated.
(due to slow accrual)
Sponsor:
Information provided by:
International Extranodal Lymphoma Study Group (IELSG)
ClinicalTrials.gov Identifier:
NCT00210366
First received: September 13, 2005
Last updated: July 29, 2010
Last verified: July 2010
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study has been terminated.
  Estimated Study Completion Date: No date given
  Primary Completion Date: July 2010 (Final data collection date for primary outcome measure)